Example: confidence
HIGHLIGHTS OF PRESCRIBING INFORMATION See Full …
chemotherapy-induced nausea and vomiting is recommended. ( 2.2) •Monitor patients during the infusion and for at least 30 minutes after completion of infusion. Treatment interruption and/or dose reduction may be needed to manage adverse reactions. (2.2) •See Full Prescribing Information for preparation and administration instructions. (2.4)
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Effexor (venlafaxine hydrochloride) Tablets …
www.accessdata.fda.govEffexor ® (venlafaxine hydrochloride) Tablets Rx only . Suicidality and Antidepressant Drugs Antidepressants increased the risk compared …
Reference ID: 3101735 - Food and Drug …
www.accessdata.fda.govDocetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
Cytotec® - Food and Drug Administration
www.accessdata.fda.govcytotec® (misoprostol) warnings cytotec (misoprostol) administration to women who are pregnant can cause abortion, premature birth, or birth defects.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govweakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms . FULL …
Namenda XR (memantine hydrochloride) capsules …
www.accessdata.fda.govThe most commonly observed adverse reactions seen in patients administered NAMENDA XR in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the
FOR INTRAVENOUS USE ONLY - Food and Drug …
www.accessdata.fda.govNDA 50-706/S-022 Page 3 MERREM® I.V. (meropenem for injection) FOR INTRAVENOUS USE ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of
NOT FOR USE IN NEONATES CONTAINS BENZYL …
www.accessdata.fda.govDepo-Medrol® methylprednisolone acetate injectable suspension, USP NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL . Not For Intravenous Use . DESCRIPTION
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govDacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and …
Venofer - Food and Drug Administration
www.accessdata.fda.govNDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of …
Diphenhydramine Hydrochloride Injection
www.accessdata.fda.govHOW SUPPLIED Diphenhydramine Hydrochloride Injection, USP is a clear and colorless solution available as: 50 mg/mL in a 1 mL prefilled single-use syringe.
Related documents
Symptom Management Guidelines: Nausea and Vomiting
www.bccancer.bc.caAny unnecessary medications contributing to nausea and vomiting should be discontinued (in consultation with physician and pharmacist) Select anti-nausea medication based on the cause of the nausea and vomiting, See . Appendix B Examples: High Risk Chemotherapy induced: add Aprepitant. Cannabis for refractory Opioid-induced nausea
Guidelines for Prevention and Treatment of Chemotherapy ...
www.bccancer.bc.caChemotherapy-Induced Nausea and Vomiting in Adults . Protocol Code . SCNAUSEA : Tumour group : SUPPORTIVE CARE . Physician Contact . Dr. Wendie den Brok . ELIGIBILITY • Adults receiving chemotherapy. • Drug acquisition: Antiemetics are considered supportive treatment. These agents are not BC
DRUG NAME: Palbociclib - BC Cancer
www.bccancer.bc.ca11. BC Cancer Agency. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012. 12. Pfizer Canada Inc. IBRANCE® product monograph. Kirkland, Quebec; 24 January 2020. 13. BC Cancer Breast Tumour Group.
DRUG NAME: Eribulin - BC Cancer
www.bccancer.bc.ca(SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer Agency; 1 Mar 2012. 7. BC Cancer Agency Breast Tumour Group. (UBRAVERIB) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast
ZOFRAN (ondansetron hydrochloride) Label
www.accessdata.fda.govabdominal surgery or chemotherapy-induced nausea and vomiting Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. (5.4) • Phenylketonuric patients should be informed that ZOFRAN ODT orally disintegrating tablets contain phenylalanine (a component of aspartame).
DRUG NAME: Oxaliplatin
www.bccancer.bc.ca(grades 3-4) diarrhea, nausea and vomiting, and neurotoxicity are more common with combination ... do not appear to reduce or protect against oxaliplat in-induced neurotoxicity. 49-52. ... Chemotherapy Preparation and Stability Chart in Appendix.
Relaxation Techniques - National Institutes of Health
files.nccih.nih.govMay 31, 2016 · chemotherapy-induced nausea, and . temporomandibular joint dysfunction. Psychological therapies, which may include relaxation techniques, can help manage . chronic headaches and other types of chronic pain in children and adolescents. Relaxation techniques have also been studied for other conditions,
The Benefits of Marijuana Legalization and Regulation
www.bjcl.orgOromucosal Standardized Cannabis Extract in Chemotherapy-induced Nausea and Vomiting, 70 J. OF CLINICAL PHARMACOLOGY 656 (2010); M. Earleywine & S.S. Barnwell, Decreased Respiratory Symptoms in Cannabis Users Who Vaporize, 4 HARM REDUCTION J. (2007); M. Earleywine et al., Case studies in cannabis vaporization, 18 ADDICTION RES.
Dental treatment considerations in the chemotherapy patient
www.medicinaoral.comHueso et al. Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases Actas Dermosifiliogr. 2008 Case series Boonyapakorn et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008 Cohort Jensen et al.
DRUG NAME: Carboplatin - BC Cancer
www.bccancer.bc.caCarboplatin Myelosuppression is the dose-limiting toxicity, usually manifested as thrombocytopenia and less commonly as leukopenia, neutropenia and anemia. Risk factors include prior cytotoxic therapy (especially cisplatin), poor performance status, old age, impaired renal function and concurrent myelosuppressive therapy.